They demonstrated that intratumoral administration of CAd-VECPDL1 combined with CAR-T cell therapy augments the anti-tumor effect of HER2-CAR-T cells and significantly prolonged animal survival in a prostate cancer xenograft mouse model compared to separated monotherapies [51]. Here, ERBB2 is linked to neoplasm.